目的 观察酒石酸长春瑞滨脂质体注射液的体内抗肿瘤作用。方法 建立小鼠肝癌H22肿瘤模型和人大细胞肺癌NCI-H460移植肿瘤模型,探讨长春瑞滨脂质体的抗肿瘤作用。结果 长春瑞滨脂质体单次以20、10、5和2.5 mg·kg-1静脉注射,对小鼠H22实体瘤的抑瘤率分别是82.1%、75.8%、63.2%和35.4%,酒石酸长春瑞滨注射液(20和10 mg·kg-1)的抑瘤率分别是45.8%和37.1%。长春瑞滨脂质体8 mg·kg-1间隔3 d静脉给药3次,可以显著抑制NCI-H460肿瘤的生长。长春瑞滨脂质体对H22肿瘤和NCI-H460的抑制作用明显优于长春瑞滨游离药,且与给药剂量正相关。结论 相同给药剂量下,长春瑞滨脂质体的体内抗肿瘤作用显著优于长春瑞滨注射液。
Abstract
To explore the anti-tumor efficacy of liposomal vinorelbine tartrate injection(NVB-lipo). METHODS The anti-neoplastic effect of NVB-lipo was evaluated by using mice bearing H22 tumor and nude mice bearing NCI-H460 human xenograft tumor model. RESULTS After a single intravenous injection at doses of 20, 10, 5 and 2.5 mg穔g-1, the inhibition ratio of H22 tumor were 82.1%,75.8%,63.2% and 35.4% respectively, and that of NVB-free(20 and 10 mg穔g-1)were 45.8% and 37.1%. After three times iv injection interval 3-day, NVB-lipo 8 mg穔g-1 could markedly inhibited the growth of NCI-H460 tumor, relative to control and NVB-free(P<0.05). The anti-tumor effect of NVB-lipo in H22 and NCI-H460 tumor model was much stronger than NVB-free, and was positively correlated with its dose levels. CONCLUSION At the same dose level, the antineoplastic effects of NVB-lipo is stronger than NVB-free.
关键词
长春瑞滨 /
脂质体 /
治疗作用 /
H22 /
NCI-H460
{{custom_keyword}} /
Key words
vinorelbine /
liposome /
anti-tumor effect /
H22 /
NCI-H460
{{custom_keyword}} /
中图分类号：
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CAPASSO A. Vinorelbine in cancer therapy.Curr Drug Targets, 2012,13(8):1065-1071.[2] BRYAN A F,TRAILOKYA N P. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer.Clin Med Insights Oncol,2011,5(10):131-144.[3] GREGORY R K,SMITH I E. Vinorelbine——a clinical review. Br J Cancer,2000,82(12):1907-1913. [4] GABIZON A,ISACSON R,LIBSON E,et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol,1994,33(7):779-786.[5] CUI J X, LI C L, GUO W M,et al. Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy. J Controlled Release, 2007,118(2):204-215.[6] SEMPIE S C,LEONE R,WANG J,et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci,2005,94(5):1024-1038.[7] ZHIGALTSEV I V,MAURER N,AKHONG Q F,et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Controlled Release,2005,104(1):103-111.[8] ZHANG L,WANG P,LI Y H,et al. Studies on vinorelbine tartrate liposomes with interior midium of ammonium sulfosalicylate. Chin Pharm J(中国药学杂志),2010,46(24):1930-1932.[9] IMMORDINO M L,DOSIO F,CATTEL L. Stealth liposomes:Review of the basic science,rationale,and clinical applications,existing and potential. Int J Nanomed,2006,1(3):297-315. WANG L F,WANG C X,WEI N,et al. Safety and antitumor effect of liposomal vinorelbine tartrate. Chin Pharm Bull(中国药理学通报), 2012,28(11):421-422.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(504 KB)
